Global DNA Vaccine Pipeline Analysis
The global market for DNA vaccines is currently recording significant growth rates owing to the lesser side effects, ease of development, lesser cost and continued development in biotechnology arena. At present, not even a single DNA vaccine has been approved for human beings. However, around 100 products are under clinical trial for treating diseases like HIV infection, cancer and other infectious diseases. With regards to animal health, there are three DNA vaccines which have been approved. The first vaccine against West Nile Virus to be used in horses was approved in 2005.
'Global DNA Vaccine Pipeline Analysis' by PNS Pharma gives comprehensive insight on the various DNA Vaccines being developed for the treatment of multiple diseases. Research report covers all the DNA Vaccines being developed in various development phases. Each DNA Vaccine profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Country of Development and detailed analysis on the development process.
This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the DNA vaccine market based upon development process. Following parameters for each DNA Vaccine profile in development phase are covered in 'Global DNA Vaccine Pipeline Analysis' research report:
- Drug Profile Overview
- Alternate Names for Drug
- Active Indication
- Phase of Development
- Mechanism of Action
- Brand Name
- Patent Information
- Orphan Designation by Indication, Country & Organisation
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- ATC Codes
- Research: 2
- Preclinical: 25
- Phase-I: 24
- Phase-I/II: 6
- Phase-II: 9
- Phase-II/III: 1
- Phase-III: 2
- Discontinued: 31
1.1 Current Market Scenario
1.2 Key Drivers for Adopting DNA Vaccine
1.3 Future Opportunity
2. DNA VACCINE DEVELOPMENT PHASE: RESEARCH
2.1 Overview
2.2 DNA Vaccine Profile in Development Phase
3. DNA VACCINE DEVELOPMENT PHASE: PRECLINICAL
3.1 Overview
3.2 DNA Vaccine Profile in Development Phase
4. DNA VACCINE DEVELOPMENT PHASE: PHASE-I
4.1 Overview
4.2 DNA Vaccine Profile in Development Phase
5. DNA VACCINE DEVELOPMENT PHASE: PHASE- I/II
5.1 Overview
5.2 DNA Vaccine Profile in Development Phase
6. DNA VACCINE DEVELOPMENT PHASE: PHASE-II
6.1 Overview
6.2 DNA Vaccine Profile in Development Phase
7. DNA VACCINE DEVELOPMENT PHASE: PHASE-II/III
7.1 Overview
7.2 DNA Vaccine Profile in Development Phase
8. DNA VACCINE DEVELOPMENT PHASE: PHASE-III
8.1 Overview
8.2 DNA Vaccine Profile in Development Phase
9. DNA VACCINE DISCONTINUED PROFILES
9.1 Overview
9.2 DNA Vaccine Profile in Development Phase
Current Market Scenario
The human DNA vaccines and animals DNA vaccines are two significant segments of the DNA vaccines market. At present, not even a single DNA vaccine has been approved for human beings. However, around 100 products are under clinical trial for treating diseases like HIV infection, cancer and other infectious diseases. Inovio Pharmaceuticals, a Pennsylvania based company has launched its vaccine with the brand name of Syncon. This is in the trial phase and once approved would cater to a variety of cancers and infectious diseases. With regards to animal health, there are three DNA vaccines which have been approved. The first vaccine against West Nile Virus to be used in horses was approved in 2005.
The total sales in the DNA vaccines market were estimated to be approximately USD xxx million in 2009. It is expected that this market would record a substantial growth rate of more than xx% to reach close to USD xx billion by 2014.
The segment of human health vaccines was estimated to be approximately USD xx million in 2009, and is expected to increase to more than USD xx billion by 2014 by recording a very high CAGR of more than xx% The research tools segment was estimated to be approximately USD xx million in 2009, and is expected to grow at a CAGR of xx% to reach USD xx million by 2014.
Some of the players in this market are Novartis Animal Health, Inovio Biomedical Corp, Merck & Co., Dendreon Corporation, Astellas Pharma, Vical, Sanofi and Tekmira Pharmaceuticals.
